News Abbott Laboratories Swiss Exchange

Stocks

ABT

US0028241000

Medical Equipment, Supplies & Distribution

Delayed Swiss Exchange Other stock markets 11:36:25 2026-06-16 EDT			5-day change	1st Jan Change
71.00 ^CHF	+0.71%		-2.07%	-28.28%

06-12	Abbott Laboratories Keeps Quarterly Dividend at $0.63 a Share, Payable Aug. 17 to Holders of Record as of July 15	MT
06-12	Abbott Laboratories Declares Quarterly Cash Dividend, Payable on August 17, 2026	CI

All News

Mentions Relevance

06-18	Big Claims, Little Kids: Recent SDNY Decision Highlights Risks In Advertising	AQ
06-12	Abbott Laboratories Keeps Quarterly Dividend at $0.63 a Share, Payable Aug. 17 to Holders of Record as of July 15	MT
06-12	Abbott declares 410th consecutive quarterly dividend	PR
06-12	Abbott Laboratories Declares Quarterly Cash Dividend, Payable on August 17, 2026	CI
06-12	BofA Adjusts Price Target on Abbott Laboratories to $102 From $120	MT
06-08	New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers	PR
06-06	Abbott Announces Dual Glucose-Ketone Sensing Technology with Libre Duo and Libre Duo 10 Day Systems	CI
06-06	New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis	PR
06-04	Abbott Labs must face lawsuit over PediaSure children's growth claims	RE
05-27	Abbott Gets CE Mark for Glucose-Ketone Sensing Technology for Diabetes	MT
05-27	Abbott secures CE mark for dual glucose-ketone sensing technology for diabetes patients	RE
05-27	Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes	PR
05-27	ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening	PR
05-27	Abbott Highlights Cologuard And Cologuard Plus As Preferred Noninvasive Colorectal Cancer Screening Options In Updated American Cancer Society Guideline	CI
05-27	Goldman Sachs Adjusts Price Target on Abbott Laboratories to $113 From $121, Maintains Buy Rating	MT
05-26	Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026	PR
05-13	NVision announced a $55 million Series B financing round anchored by Abbott	RE
05-12	NVISION IMAGING Technologies GmbH announced that it has received $38 million in funding from b2venture AG, Playground Global, LLC, Entrée Capital Limited, Matterwave Ventures Management GmbH, Abbott Laboratories and other investors	CI
05-05	Abbott Laboratories Pick of the Week at Smart Insider Following CFO Stock Purchase	MT
04-30	Abbott Laboratories : to highlight expanding cancer diagnostic portfolio and clinical evidence at Digestive Disease Week (DDW) 2026	PU
04-29	Tranche Update on Abbott Laboratories's Equity Buyback Plan announced on October 16, 2024.	CI
04-28	Abbott Laboratories Says Ultreon 3.0 Coronary Imaging Software Receives FDA Clearance, CE Mark	MT
04-28	Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform	PR
04-28	Abbott Receives Fda Clearance for Next-Generation Ultreon 3.0 Ai-Powered Coronary Imaging Platform	CI
04-27	Abbott Laboratories Announces Board Changes	CI